AU2002212895A1 - N-type calcium channel antagonists for the treatment of pain - Google Patents
N-type calcium channel antagonists for the treatment of painInfo
- Publication number
- AU2002212895A1 AU2002212895A1 AU2002212895A AU1289502A AU2002212895A1 AU 2002212895 A1 AU2002212895 A1 AU 2002212895A1 AU 2002212895 A AU2002212895 A AU 2002212895A AU 1289502 A AU1289502 A AU 1289502A AU 2002212895 A1 AU2002212895 A1 AU 2002212895A1
- Authority
- AU
- Australia
- Prior art keywords
- pain
- treatment
- calcium channel
- type calcium
- channel antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0004054 | 2000-11-06 | ||
| SE0004054A SE0004054D0 (en) | 2000-11-06 | 2000-11-06 | N-type calcium channel antagonists for the treatment of pain |
| PCT/SE2001/002389 WO2002036567A1 (en) | 2000-11-06 | 2001-10-31 | N-type calcium channel antagonists for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002212895A1 true AU2002212895A1 (en) | 2002-05-15 |
Family
ID=20281714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002212895A Abandoned AU2002212895A1 (en) | 2000-11-06 | 2001-10-31 | N-type calcium channel antagonists for the treatment of pain |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7189714B2 (en) |
| EP (1) | EP1339688A1 (en) |
| JP (1) | JP2004513116A (en) |
| AU (1) | AU2002212895A1 (en) |
| SE (1) | SE0004054D0 (en) |
| WO (1) | WO2002036567A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020121638A1 (en) * | 2000-06-30 | 2002-09-05 | Vladimir Grushin | Electroluminescent iridium compounds with fluorinated phenylpyridines, phenylpyrimidines, and phenylquinolines and devices made with such compounds |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| DE10316659A1 (en) * | 2003-04-11 | 2004-10-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tricyclic heteroaromatic compounds |
| WO2005000285A2 (en) * | 2003-06-13 | 2005-01-06 | Dynogen Pharmaceuticals, Inc. | METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS |
| RU2440991C2 (en) * | 2004-09-02 | 2012-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Quinazoline effective as ion channel modulators |
| US8084260B2 (en) * | 2004-11-24 | 2011-12-27 | Applied Biosystems, Llc | Spectral calibration method and system for multiple instruments |
| ATE453638T1 (en) * | 2006-07-31 | 2010-01-15 | Rottapharm Spa | AMIDENE DERIVATIVES OF 2-HETEROARYLQUINAZOLINES AND QUINOLINES; EFFECTIVE ANALGESICS AND ANTI-INFLAMMATORY AGENTS |
| US8987301B2 (en) | 2009-11-07 | 2015-03-24 | Merck Patent Gmbh | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors |
| EP2549872B1 (en) * | 2010-03-23 | 2015-11-25 | GlaxoSmithKline LLC | Trpv4 antagonists |
| WO2011119693A1 (en) * | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Trpv4 antagonists |
| AU2011321310B2 (en) * | 2010-10-29 | 2016-02-11 | Clino Ltd. | Tau imaging probe |
| CA2922542A1 (en) * | 2013-11-22 | 2015-05-28 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| CA3227251A1 (en) * | 2021-08-09 | 2023-02-16 | Jianguang HAN | Ferroptosis modulators, preparations, and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2568778A (en) * | 1948-05-28 | 1951-09-25 | Sterling Drug Inc | Tertiary-aminoalkyl-alpha-arylalpha-(4-quinolyl) acetates and amides and their preparation |
| US2616889A (en) * | 1948-07-05 | 1952-11-04 | Roussel Uclaf | Condensation products of the sugars with derivatives of esculetol and process |
| GB794043A (en) * | 1955-06-03 | 1958-04-30 | Ici Ltd | New quinoline derivatives |
| US4816588A (en) * | 1986-09-12 | 1989-03-28 | American Cyanamid Company | Method for the preparation of pyridine-2,3-dicarboxylic acids |
| HUP0101275A3 (en) * | 1998-03-26 | 2002-12-28 | Japan Tobacco Inc | Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| US6927214B1 (en) * | 1999-01-15 | 2005-08-09 | Novo Nordisk A/S | Non-peptide GLP-1 agonists |
-
2000
- 2000-11-06 SE SE0004054A patent/SE0004054D0/en unknown
-
2001
- 2001-10-31 EP EP01981240A patent/EP1339688A1/en not_active Withdrawn
- 2001-10-31 JP JP2002539327A patent/JP2004513116A/en active Pending
- 2001-10-31 US US10/415,853 patent/US7189714B2/en not_active Expired - Fee Related
- 2001-10-31 WO PCT/SE2001/002389 patent/WO2002036567A1/en active Application Filing
- 2001-10-31 AU AU2002212895A patent/AU2002212895A1/en not_active Abandoned
-
2006
- 2006-08-23 US US11/466,562 patent/US7348340B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20040077644A1 (en) | 2004-04-22 |
| US7348340B2 (en) | 2008-03-25 |
| US20070129363A1 (en) | 2007-06-07 |
| US7189714B2 (en) | 2007-03-13 |
| WO2002036567A1 (en) | 2002-05-10 |
| JP2004513116A (en) | 2004-04-30 |
| EP1339688A1 (en) | 2003-09-03 |
| SE0004054D0 (en) | 2000-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1425277B8 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
| GB0007193D0 (en) | Treatment of movrmrnt disorders | |
| HK1051690A1 (en) | Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain. | |
| AU2002212895A1 (en) | N-type calcium channel antagonists for the treatment of pain | |
| AP2001002268A0 (en) | Gardos channel antagonists | |
| GB0213869D0 (en) | The treatment of pain | |
| IL151891A0 (en) | Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
| IL151765A0 (en) | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | |
| AU2003237969A1 (en) | Pharmaceutical composition comprising calcium channel blockers for the treatment of pain | |
| AU2002212896A1 (en) | N-type calcium channel antagonists for the treatment of pain | |
| GB0020588D0 (en) | Treatment of wounds | |
| AU2003266960A1 (en) | Composition for the treatment of pain, especially for the treatment of articular pain | |
| AU2002326276A1 (en) | N-type calcium channel antagonists for the treatment of pain | |
| AU2002324407A1 (en) | N-type calcium channel antagonists for the treatment of pain | |
| AU2683500A (en) | Compositions for the treatment of pain | |
| AU2002228911A1 (en) | Methods for inhibiting pain | |
| AU2002315522A1 (en) | Receptor agonists useful for the treatment of pain | |
| AU2000272704A1 (en) | Use of compounds for the treatment of obesity | |
| AU2001274446A1 (en) | Vip-related peptides for the treatment of skin disorders | |
| AU2002238460A1 (en) | Regulation of human calcium channel | |
| AUPQ790900A0 (en) | Treatment for scrubber effulent | |
| AU2002327697A1 (en) | Compounds for the treatment of pain | |
| AU2002216996A1 (en) | Mixture for treating skin | |
| AU2002336574A1 (en) | Methods of using 5433, a human calcium channel family member |